CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use

Most people who choose CJC 1295 with DAC do it because fewer injections sounds like a straightforward win, and on the surface that logic holds up. The peptide still works, the half life extends, and you get sustained growth hormone elevation without pinning every day. What that reasoning misses is that the delivery pattern itself is doing a job, and extending the half life changes the pattern in a way that undermines the whole reason you chose a secretagogue in the first place.

To understand why that matters, you need the full picture of how growth hormone actually works in your body before a peptide ever enters it.

Your pituitary gland releases growth hormone in pulses, not as a steady stream. These pulses fire several times throughout the day and night, with the largest ones happening during deep sleep, and between each pulse the level drops back down close to zero. Those valleys are not a problem to be solved. They are part of the mechanism. The pulsatile pattern is what drives lipolysis, which is the process your body uses to pull fat out of storage and break it down for fuel, and it is what signals your tissues to produce IGF-1, the downstream growth factor responsible for most of growth hormone's anabolic effects.

So the goal, if you are going to use a secretagogue, is to amplify that system without dismantling it.

CJC 1295 without DAC does exactly that. It is a modified version of growth hormone releasing hormone, which is the signal your hypothalamus sends to the pituitary to trigger a pulse. When you inject it, you get a burst of growth hormone that mirrors what a natural pulse looks like. The peptide has a half life of roughly 30 minutes, so it clears out relatively quickly, and your pituitary goes back to firing its own pulses in between doses. Your body's rhythm stays intact. You are essentially adding pulses on top of the ones that are already happening.

Now here is where DAC changes things at the structural level.

DAC stands for drug affinity complex, and it is a modification that lets the peptide bind to albumin, which is a protein that floats throughout your bloodstream and is already being used to transport other molecules. When CJC 1295 binds to albumin, it stops being cleared quickly, and that extends the active half life from 30 minutes to somewhere between 5.8 and 8.1 days based on clinical data. One injection lasts essentially a full week.

What that produces is not a stronger pulse. It is a floor. Your pulsatile activity continues, meaning your pituitary still fires at its normal rhythm, but now the baseline between every pulse is elevated roughly 7.5 times above where it would normally sit. The valleys fill in. The trough GH level, the point that is supposed to drop close to zero between pulses, stays persistently elevated for the entire duration the peptide is active. Your pattern shifts from a sharp wave pattern with real highs and real lows to something that looks more like a flat, elevated plateau with small oscillations on top of it.

That distinction matters more than it might seem.

A study published in the Journal of Clinical Endocrinology and Metabolism in 2009 compared what happened in obese subjects when growth hormone was delivered in a pulsatile pattern versus a continuous one. Pulsatile delivery brought lipolysis from a baseline of 4.1 up to 7.1 micromoles per kilogram per minute, nearly doubling fat breakdown. Continuous delivery moved the number to 4.8, which was not statistically different from doing nothing. The hormone was present in both cases. The receptor was available in both cases. The difference was entirely in the pattern of delivery, and pulsatile won by a significant margin.

The mechanism behind this likely comes down to receptor behavior. Continuous stimulation of the growth hormone releasing hormone receptor triggers what is called homologous downregulation, where the receptor reduces its own sensitivity in response to uninterrupted signaling. Research from 1997 showed that just four hours of continuous GHRH exposure was enough to drop GHRH receptor messenger RNA to between 49 and 54 percent of baseline levels, and the effect was dose dependent. The receptor is essentially telling the cell to turn down its own ears when the signal never stops. Pulsatile delivery avoids this because the signal keeps switching on and off, giving the receptor time to reset between stimulations.

This is the structural problem with DAC. It keeps the GHRH signal continuously elevated, which is the exact condition that triggers receptor downregulation, and it fills in the troughs that make pulsatile delivery metabolically effective. You are paying for both problems at once.

There is also a positioning problem. If someone decides the goal is sustained, continuous growth hormone elevation, that is a legitimate strategy with decades of clinical data, known dosing protocols, and predictable outcomes because they would be using actual growth hormone directly. DAC puts you in a position where you lose the pulsatile advantage that makes a secretagogue worth using, but you also do not get the precision or the established track record of exogenous growth hormone. It occupies a middle space that has the drawbacks of both approaches without the full benefits of either.

The version without DAC does what a secretagogue is supposed to do. It works with the pulsatile system your body already runs, amplifies the signal without replacing it, and clears quickly enough that your natural rhythm can continue firing between doses. The fewer injections argument is not wrong on convenience, but convenience only matters if the thing you are taking is actually doing what you want it to do.

Your body does not respond to how often you inject. It responds to the shape of the signal you create, and the shape is everything.

---

References

1. Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
3. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
4. Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness